Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc AGNPF


Primary Symbol: C.AGN

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals Announces Public Offering of Units

GlobeNewswire June 15, 2022

Algernon Pharmaceuticals (CSE:AGN) locks in Phase 2 results of IPF & chronic cough study

Jonathon Brown June 13, 2022

Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough

GlobeNewswire June 13, 2022

Algernon Pharmaceuticals (CSE:AGN) treats last patient in phase 2 IPF and chronic cough study

Trevor Abes  May 5, 2022

Algernon Pharmaceuticals Announces Last Patient Treated in Phase 2 Study of IPF and Chronic Cough

GlobeNewswire May 5, 2022

Algernon Pharmaceuticals (CSE:AGN) reports positive findings in lead chronic kidney disease drug, Repirinast

Brieanna McCutcheon  April 26, 2022

Algernon Pharmaceuticals Announces Lead Chronic Kidney Disease Drug Repirinast Reduced Fibrosis by 56% in a Preclinical NASH Study

GlobeNewswire April 26, 2022

Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program

GlobeNewswire February 23, 2022

Canadian Pharma Co. Advances Chronic Cough Study

Stockhouse Editorial February 4, 2022

Algernon Pharmaceuticals (CSE:AGN) completes enrollment in its Phase 2 study of Ifenprodil

John Ballem  February 4, 2022

Algernon Pharmaceuticals Announces Completion of Enrollment in its Phase 2 Study of Ifenprodil for IPF and Chronic Cough

GlobeNewswire February 4, 2022

Introducing Algernon Pharmaceuticals (CSE:AGN)

John Ballem  February 2, 2022

Algernon Pharmaceuticals (CSE:AGN) receives notice of allowance for Ifenprodil

Caroline Egan  January 28, 2022

Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent Application for Idiopathic Pulmonary Fibrosis

GlobeNewswire January 28, 2022

The Power Play by The Market Herald Releases Interviews with Algernon Pharmaceuticals, Newrange Gold, and Fokus Mining

Accesswire January 24, 2022

Algernon Pharmaceuticals (CSE:AGN) discloses novel salt patent strategy

John Ballem  January 24, 2022

Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property

GlobeNewswire January 24, 2022

The Power Play by The Market Herald Releases Interviews With Xali Gold, Falcon Gold, Psyched Wellness, Argentina Lithium, and Algernon Pharmaceuticals

Accesswire January 19, 2022

Algernon Pharmaceuticals (CSE:AGN) files for approval for Phase 1 DMT Human Stroke Study

John Ballem  January 19, 2022

Algernon Pharmaceuticals Files for Clinical Trial and Ethics Approval for Phase 1 DMT Human Stroke Study

GlobeNewswire January 19, 2022